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Primary breast lymphoma (PBL) in men 
— a systematic review
ABSTRACT
Primary breast lymphoma (PBL) is a rare type of lymphoma, especially in men. Details of the clinical course are 
not well recognized, and a consensus on the treatment of PBL in male is not available. The objective of presenting 
this study was to find the most common presentation and the best treatment options for male PBL by collecting 
and analysing data of all reported cases published between 1985 and 2019. 
A comprehensive search in Google Scholar, Ovid Medline, PubMed, and Scopus databases for any case of PBL 
presenting in men between 1985 and 2019 was performed. Patient information such as age, diagnosis, type of 
treatment(s), time to follow-up and patient status were recorded.
A total of 28 studies containing data of 34 male patients with PBL were included in this review. The mean age 
of patients was about 61 (range: 26–85) years. The mean tumour size was 46.05 ± 20.37 mm. The majority of 
cases were presented with a palpable breast mass (unilateral or bilateral). Nine patients (26.5%) had previous 
comorbidities. Diffuse large B cell lymphoma was the most common histologic diagnosis (85.3%). Treatment 
consisting of systematic therapy combined with radiotherapy showed benefit outcome.
The results of the analysis showed that the response to different therapies was better in younger patients with 
PBL. It seems that systemic therapy combined with at least a 30 Gy dose of radiation has the best outcome in 
male patients with PBL. Considering limited data in each group of treatment modality, further follow-up studies 
in these patients are necessary.
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Introduction
Primary breast lymphoma (PBL) is a rare type of lym-
phoma involving only the breast, with or without axillary 
lymph nodes; and no extra-mammary disease [1, 2]. Over-
all, PBL accounts for approximately 1% of non-Hodgkin 
lymphomas (NHL) [3], less than 3% of extranodal lympho-
mas, and 0.5 % of breast malignancies [4]. More than 95% 
of PBL cases are female and the most frequent histological 
subtype is diffuse large B-cell lymphoma (DLBCL) [5, 6]. 
Owing to the limited number of male patients, de-
tails of treatment or clinical course are not sufficiently 
reliable, and no standard therapy has been established. 
Local control seems poor with surgical resection alone, 
so the combination of chemotherapy and radiation has 
been recommended [6, 7]. 
This review aimed to find all published cases of male 
PBL to understand the course of disease more precisely 
and also to reach a consensus about the optimal therapy. 
Methods
Search strategy
A comprehensive search was performed in Google 
Scholar, Ovid Medline, PubMed, and Scopus databases 
for any case or detail of PBL presenting in men between 
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1985 and 2019. This date range was chosen because the 
earliest study was found in 1985. The keywords “breast” 
OR “mammary” AND “lymphoma” combined with 
“male” OR “man” OR “men” were used for the search. 
The initial screening was based on titles and abstracts of 
the returned results. Studies were included if they con-
tained information about male patients with PBL and 
excluded if they reported secondary involvement of the 
breast in lymphoma, or did not report the male patient 
data in detail. To avoid bias with linguistic restriction, at 
first, the studies were selected regardless of the language 
of publication. Papers with available English abstracts 
were included in the first screening. In the next stage, full 
texts of all selected abstracts were studied. As in the first 
screening, articles that contained PBL as defined previ-
ously were included. Non-English papers were included 
if the abstract gave all the necessary information. Refer-
ences and tables of the included articles were also checked 
out for any omitted study, and detected papers were 
screened and included with the same criteria thereafter. 
Types of studies selected
All observational studies (case report, case series) 
that reported PBL presenting in men were selected. 
Because of the scarcity of PBL in male, all studies were 
included even by incomplete data.
Data extraction 
A data extraction form was designed a priori and three 
academic experts (two breast surgeon and one investiga-
tor) confirmed its face validation and ease of use for data 
extraction. Data items consisted of the name of the first 
author, publication year, patient’s age, laterality of breast 
mass, tumour size, first presentation, diagnosis, stage of the 
disease, treatment, drug and comorbidity history, follow-up 
time and status. Patients’ outcomes were categorized as no 
evidence of disease (NED); alive with the disease (AWD); 
dead of disease (DOD). Two reviewers extracted the data 
out of the included studies independently, and all data was 
checked by a third party. Continuous and proper monitoring 
of newly published papers went on until final data extraction.
Statistics
The statistical analyses were performed using IBM 
SPSS 26 (IBM Corp. Released in 2016. IBM SPSS Statis-
tics for Windows, Version 24.0. Armonk, NY: IBM Corp).
Results
Totally 28 studies containing data of 34 male patients 
with PBL were included in this review (Tab. 1). Two 
studies had no English full text, so data was limited to the 
abstracts [8, 9]. The data of 5 cases were extracted from 
one study which was a case report and review article [10] 
and the review part of this study included data of 4 cases 
whose original articles (case reports) were not found.
Data of the 34 PBL male cases are summarized in 
Table 2. The mean age of patients was about 61 (range: 
26–85) years. The majority of cases presented with 
a palpable breast mass (unilateral or bilateral). Nine 
patients (26.5%) had previous comorbidities including 
other cancers, HIV, hepatitis, cirrhosis, and previous 
history of a kidney transplant. Ten cases in this review 
had gynecomastia (4 bilateral & 6 unilateral) and one 
of the patients was transgender. Three patients had 
a previous history of hormone therapy with oestrogen 
(3 m, 5 y, and 9 y), two patients received hormone 
therapy (hormone pills and sex hormone), one patient 
had received 10 years of immunosuppressive therapy, 
and the other had undergone antiviral treatment for 
4 years. Two patients had a brain and adrenal metastasis.
The most frequent histopathology was DLBCL, re-
ported in 29 (85.3%). As far as information was available, 
the majority of patients in stage I (14 patients) reported 
no evidence of disease at the time of follow-up. Chemo-
therapy was the most frequently administered therapy and 
27 patients had received chemotherapy, alone (8 patients) 
or in combination with surgery or radiotherapy (15 pa-
tients). Multi-agent chemotherapy consisted of CHOP 
(cyclophosphamide, adriamycin, vincristine, predniso-
lone) or CHOP-like regimen in 15 patients. Four out of 
five patients (80%) with available status received immu-
nochemotherapy (R-CHOP: rituximab + CHOP) showed 
complete remission and one patient was alive with disease. 
However, in 9 patients who treated with CHOP without 
rituximab, two deaths occurred and one patient was alive 
with disease. Five patients were treated only by surgery. 
Treatment data of three patients were not available.
The treatment and outcome were not available 
in seven patients and one patient died due to other 
condition (cerebrovascular accident) while the final 
information about the outcome of their lymphoma was 
not reported. Therefore, after the mean follow up time 
of 19 months (range: 0–123) in 27 patients, the number 
of patients with NED, AWD, and DOD outcomes were 
19, 3, and 5, respectively. In Table 3 are demonstrated 
the effects of some variables on disease outcomes (Alive 
or Dead) in 27 patients. Eight patients who received 
radiotherapy combined with other modality were alive. 
Discussion
The breast is a rare extranodal site of involvement 
by lymphoma, especially in men. However, breast lym-
phoma should be included in the differential diagnosis 
of breast masses in male patients, particularly in immu-
nocompromised ones [11]. 
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Table 1. Characteristics of 34 male pr imary breast lymphoma patients
No Ref Author, Year Age Laterality Diagnosis Stage Chemotherapy RT, Gy Surgery Follow-up 
(month)
Status
1 24 López-Rodríguez, 
2019
81 Lt DLBCL IE 4 ×  CP Y, NA No 0 NED
2 29 Bozkaya, 2019 82 Bilateral DLBCL IIIA 2 × R-CHOP No No 0 NED
3 30 Jonckheere, 2019 80 Lt DLBCL NA NA NA NA NA NA
4 8 Tokuyama, 2017 74 Rt DLBCL IIA 6 × R-CHOP  
+ 4 × intrathecal 
No No 0 NED
5 9 Goto, 2017 85 Rt DLBCL NA NA NA NA NA NA
6 25 Corobea, 2017 56 Rt DLBCL IE 3 × R-CHOP  Y, 50Gy MRM 17 NED





8 10 Ishibashi, 2016 69 Unknown DLBCL IIE Poly No MRM 18 DOD
9 10 Ishibashi, 2016 45 Unknown DLBCL IIE No No Tumour 
excision
5 NED
10 10 Ishibashi, 2016 65 Unknown DLBCL IE Poly No MRM 20 NED
11 10 Ishibashi, 2016 81 Unknown LL NA No No MRM 4 AWD
12 11 Yim, 2015 63 Lt DLBCL IE R-CHOP No No 11 AWD
13 31 Jung, 2014 46 Rt FL IEA No No Surgery 40 NED
14 32 Lokesh, 2013 60 Lt SLL IIEA 9 ×  (COP) No No Lost  to 
follow-up
NA
15 32 Lokesh, 2013 46 Rt DLBCL IIEA 3 × CHOP No No 0 Dead
16 33 Mukhtar, 2013 50 Lt DLBCL IIB CHOP Y, 50Gy No 0 NED
17 34 Mouna, 2012 76 Lt DLBCL IBE No No Tumour 
Excision
3 DOD
18 35 Ko, 2012 51 Lt DLBCL IA 5 × CHOP No No 12 NED
19 36 Rastogi, 2012 48 Rt DLBCL IE CHOP No No 0.63 DOD
20 37 Li, 2012 33 Rt DLBCL IA CHOP No MRM 29 NED
21 37 Li, 2012 63 Rt DLBCL IA No No Tumour 
Excision
NA NA
22 26 Alhabashi, 2011 26 Rt DLBCL II 6 × CHOP Y, 40±50Gy No 24 NED
23 38 Rathod, 2011 48 Lt DLBCL II 14 × CHOP No No 7 AWD
24 39 Duman, 2011 62 Lt MZBL IIE R-CHOP Y, NA Tumour 
Excision
NA NA
25 40 Mahmood, 2011 50 Lt DLBCL IIE NA NA NA NA NA
26 27 Miura, 2009 64 Lt DLBCL IEA 6 × R-CHOP Y, 50Gy No 12 NED
27 41 Gualco, 2009 65 Rt ALCL IE Yes Y, NA No 18 Alive
28 42 Mpallas, 2004 67 Rt DLBCL II Yes No MRM 12 DOD
29 28 Cabras, 2004 44 Lt DLBCL IIAE ACOP-B Y, 36Gy Tumour 
Excision
123 NED
30 43 Evans, 2002 27 Lt DLBCL IA Poly No No NA NED
31 20 Sashiyama, 1999 69 Lt DLBCL IE 3 × CHOP No MRM 12 NED
32 44 Hinoshita, 1998 65 Lt DLBCL IIAE CPA, VDS,  
6-mercaptopurine, 
Daunorubicin, PSL
No LMRM 24 NED
33 45 Murata,1996 76 Rt DLBCL IE 5 × post-op 
CHOP 
No RMRM 39 NED
34 1 Hugh, 1990 81 Bilateral DLBCL IE Yes No No 5 DOD
Rt — right; Lt — left; ALN — axillary lymph node; DLBCL — diffuse large B cell lymphoma; LL — Lymphoblastic lymphosarcoma; FL — follicular lymphoma; 
SLL — small lymphocytic lymphoma; MZBL — marginal zone breast lymphoma; Poly — multiagent chemotherapy; RT — radiotherapy; MRM — modified 
radical mastectomy; LMRM — left MRM; RMRM — right MRM; CP — cyclophosphamide and prednizone; CHOP — cyclophosphamide; adriamycin; vincristine; 
prednisolone; R-CHOP — rituximab + CHOP; ACOP-B — doxorubicin; cyclophosphamide; vincristine; prednisone; bleomycin; NA — not available; NED — no 
evidence of disease; AWD — alive with the disease; DOD — dead of disease
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Table 2. Patient and disease characteristics of all patients
Variables
Continuous variables Min–Max Mean ± SD
Age [years] 26–85 60.97 ± 16.04
Tumour clinical size [mm] 20–85 46.05 ± 20.37
Follow-up [months] 0–123 16.43 ± 24.16
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PBL includes a lesion in the breast with or without 
the involvement of axillary lymph nodes, without any 
other extra-mammary lesion and a technically adequate 
pathologic exam confirms the presence of breast tissue 
near lymphoma [12, 13]. Diagnosis of primary breast 
non-Hodgkin lymphoma needs adequate histologic eval-
uation, presence of breast tissue close to the lymphoma 
in the specimen, no previous diagnosis of lymphoma, 
and no extramammary disease except ipsilateral axillary 
lymph nodes [1, 4]. The most common subtype is diffuse 
large B-cell lymphoma (DLBCL), but other subtypes 
including follicular lymphomas (FL), mucosa-associat-
ed lymphoid tissue (MALT) lymphomas and Burkitt’s 
lymphomas (BL) are also seen [6, 14]. 
Because of the rarity, only a few scattered reports 
of these cases are published and many published 
series of breast lymphoma are a mixture of patients 
with PBL, extra-mammary lymphoma, secondary 
breast lymphoma, and recurrence of lymphoma in 
the breast. Additionally, many of the articles reported 
both male and female cases, so accurate and detailed 
data on the clinical course of the disease in men; its 
treatment and follow up is limited. The increasing 
number of reports in the recent past few years may 
represent increasing awareness toward the disease 
and the need for a comprehensive agreement about 
the management. 
Age and laterality
The mean age of patients in this study (60.97 ± 16.04) 
was compatible with other studies [1, 4, 15]. In contrast 
to the Hugh et al. [1] study in women diagnosed with 
PBL (2 out of 20 cases were male) and Uesato study in 
Japanese cases (9 out of 380 cases were male) [16], that 
showed younger cases had poorer prognosis and lower 
survival, the result of the current study in males showed 
that younger male cases had a better response to differ-
ent therapies. Furthermore, left breast involvement in 
the authors’ review of male patients was more common, 
however, the involvement of the right breast was more 
frequently observed in women [1, 4, 6, 15]. Bilateral in-
volvement was seen in 3 patients (8.8%), nearly similar 
to female studies which reported bilaterality in 4–13% 
at the time of diagnosis [1, 4, 6, 15]. Based on previous 
studies, bilateral breast disease was thought to be as-
sociated with aggressive disease [17]. In the presented 
study, 1 out of 3 (33.3%) patients with bilateral PBL died 
of the disease, whereas the frequency of death due to 
PBL was 11.1% in unilateral cases (2 out of 18). These 
numbers are too small for any deduction; it can only be 
said that bilateral male patients with PBL had poorer 
outcome regarding disease-related death.
Comorbidity and drug consumption
In this review, nine cases had a previous history of co-
morbidities. Three common comorbidities were cancer, 
HIV positivity, and Cirrhosis. Overall, it is known that 
non-Hodgkin lymphoma is the second most common 
AIDS-associated malignancy [18]. In this review two 
patients were HIV-positive and one of them died after 
19 days of treatment, which consisted of a CHOP reg-
imen only. Ten reviewed cases had gynecomastia, and 
five patients had a history of hormone therapy.
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Sex hormone dependency was reported in two 
female cases of a study with 20 PBL cases (all but two 
cases were female patients) and their tumour cells were 
positive for estrogen and progesterone receptors [1]. 
Also, a large cohort study in women has shown that the 
risk of non- Hodgkin lymphoma in females who received 
oestrogen therapy was 29% higher than those who never 
used hormone therapy, for follicular lymphoma and 
DLBCL [19]. This evidence suggests that non-Hodgkin 
lymphoma in the male breast may involve patients with 
elevated oestrogen levels [20]. Although the role of 
oestrogen in the aetiology of this disease is not clear, 
several biologic mechanisms like immunomodulatory 
effects have been proposed [19]. Meanwhile, the rare 
occurrence of PBL in males may suggest a role for oes-
trogen in its pathogenesis.
Treatment 
Due to the heterogeneity of the information, com-
parison of cases and conclusion on the best treatment 
method in PBL male patients is not possible but it seems 
that in recent studies with a majority of women cases, 
a non-surgical approach is preferred and chemotherapy 
has become the first choice of therapy either in com-
bination with other treatment strategies (radiation and 
surgery) or alone. 
The result of a large retrospective study in 204 cases 
(including five male patients) of DLBCL of the breast 
with various types of treatment regimen reported that 
anthracycline-containing chemotherapy and radiation 
therapy was associated with longer survival, and mastec-
tomy had no benefit as opposed to biopsy or lumpectomy 
alone; the authors proposed that extensive surgeries may 
have detrimental effects by delaying the commencement 
of systemic therapy [6]. This study reported the outcome 
for males did not differ from female cohort cases, with 
5-year overall survival of 60% and a wide confidence 
interval due to the small sample size of male patients [6]. 
In a Japanese article of 380 cases (including 9 men) of 
PBL [16], they concluded that five-year survival for stage 
I and II was lower by surgical treatment alone compared 
with surgery and systemic therapy (40.5% and 25% 
vs. 57.2% and 47%). They also showed that minimal sur-
gery for confirming diagnosis and planning treatment was 
necessary, but mastectomy, wide local excision, and axil-
lary dissection seemed unnecessary. They did not report 
the results of treatment in females and males separately. 
Table 3. Disease outcome based on tumour features, patient comorbidity and type of treatment.















































































Data are presented as mean ± standard deviation and number with percentages in parenthesis; DLBCL — diffuse large B-cell lymphoma; ALCL — anaplastic 
large cell lymphoma; FL — follicular lymphoma; LL — lymphoblastic lymphosarcoma; RT — radiotherapy; NED — no evidence of disease; AWD — alive with 
the disease; DOD — dead of disease
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ESMO Guideline in 2016 confirmed surgical resec-
tion is inadequate in local control and mastectomy is 
associated with poor outcomes and they suggested that 
initial surgery should be offered only if chemotherapy 
delays can be avoided [21].  
In the present review of PBL presenting in men, 1 out 
of 4 patients who were treated by surgery alone died due 
to lymphoma. One patient was alive with the disease 
after 4 months and two patients were alive with no 
evidence of disease after 5 and 40 months of follow-up. 
Although the majority of the previously reported studies 
were conducted in female patients, the presented study 
can confirm that surgery is not an appropriate treatment 
for male PBL patients. 
The role of radiotherapy in local control of PBL was 
shown in many studies [1]. Radiotherapy is considered 
for the prevention of subclinical disease in the breast, 
however, the optimal dose and radiation fields are vari-
ous among different reports. A randomized prospective 
study by Avilés on 96 patients with PBL in the early 
stage is consistent with the presented study finding 
and showed a better survival for patients who received 
combined chemotherapy and radiation therapy com-
pared to either therapy alone [22]. The median dose 
in most studies was 40 Gy (range 30.6 to 60 Gy) [1, 15] 
and involved site radiotherapy include ipsilateral breast 
plus any additional site of pre-chemotherapy disease in 
the regional node or contralateral breast has replaced 
involved-field radiotherapy [12]. Radiotherapy to 
the whole breast with a dose of 30 Gy after receiving 
R-CHOP for complete response is recommended [23]. 
Interestingly in the present review, all eight male 
patients who received radiotherapy combined with 
other treatment modality were alive without evidence 
of disease after a median of 17 months [10, 24–28]. 
Four patients received higher than 30 Gy (they mostly 
received 50 Gy), and information about radiation dosage 
was not available in one patient [24]. 
The presented data may confirm that chemother-
apy (with or without rituximab) is the optimal choice 
in combination with other modalities, especially with 
radiotherapy (Tab. 3) in male patients. However, 
chemotherapy alone didn’t provide a good prognosis, 
as 2 out of 9 (22.2%) deaths occurred in those who 
received chemotherapy alone and 2 cases were alive 
with disease. In patients who received immunochemo-
therapy (R-CHOP), 80% had complete remission, and 
only one patient who didn’t receive another modality is 
alive with disease. 
ESMO clinical guideline in 2016, confirmed ritux-
imab improves the progression-free survival and overall 
survival in PBL patients [21]. Although ESMO recom-
mended six cycles of R-CHOP plus RT in patients who 
tolerate therapy well [21], the review of male cases shows 
five patients who received R-CHOP less than 6 cycles 
(2–5 cycles) were alive without evidence of disease 
during follow-up time (Tab. 1). It may be related to 
a hormone dependency of this disease and the differ-
ence in hormonal profiles of males and females. Further 
studies in male patients are recommended to find less 
aggressive treatment.   
Study limitation 
Considering limited data and a scant number of 
patients in each group of treatment modality, any con-
clusions about the best treatment strategy in male PBL 
seems impossible. 
Conclusions
For the time being, with rely on female’s studies, 
which have shown that surgery has no therapeutic role 
beyond obtaining a histologic diagnosis to guide defini-
tive treatment of PBL, the presented results in males also 
show surgery is not a good choice for treatment of PBL.
The presented study concludes some differences 
between previous female studies and males in the pre-
sentation of PBL disease, prognosis, and treatment. 
In contrast with females, left breast involvement in 
male patients was more common and younger age 
is associated with better outcomes and prognosis. In 
similar to females patients’ treatment, immunotherapy 
accompanied with radiotherapy with a dose of at least 
30 Gy, is the optimal treatment in male patients too, 
however, it seems fewer immunotherapy cycles may be 
enough to complete recovery. Further reports and series 
of the long-term follow-up of male patients with PBL 
after treatment are necessary to compare outcomes and 
achieve a consensus about a standard treatment strategy. 
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